Evorpacept + Fam-Trastuzumab Deruxtecan-Nxki (ENHERTU®)
HER2-positive Metastatic Breast Cancer
Phase 1/1bRecruiting
Key Facts
About ALX Oncology
ALX Oncology is a clinical-stage biotech focused on developing evorpacept, a next-generation CD47 inhibitor engineered to minimize toxicity while promoting macrophage-mediated tumor destruction. The company's core strategy is to develop evorpacept as a synergistic backbone therapy in combination with established and emerging oncology agents, with multiple Phase 2 trials underway. Key achievements include establishing proof-of-concept in gastric cancer and securing strategic collaborations with major pharmaceutical partners to expand its clinical reach.
View full company profileTherapeutic Areas
Other HER2-positive Metastatic Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| [vic-]trastuzumab duocarmazine (SYD985) | Byondis | Phase 3 |